Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho, MOF Agree on 0.38% Increase in Medical Fees
January 7, 2008
- GENERICS NEWS IN BRIEF
January 7, 2008
- Gov't Decides to Increase Medical Fees 0.38%
January 7, 2008
- Geninax Captures 1st Place in October
December 24, 2007
- BUSINESS NEWS IN BRIEF
December 24, 2007
- Re-Pricing, Special Price Cut to Be Less Harsh Than in FY2006: FY2008 Price Revision
December 24, 2007
- Bargaining over Revision Rates Enters Final Stage
December 24, 2007
- 16 Products (9 APIs) Receive NHI Price Listing
December 24, 2007
- 79 Deaths Reported in Patients Taking Enbrel: Wyeth
December 24, 2007
- REGULATORY NEWS IN BRIEF
December 24, 2007
- TOPICS／Takeda Regarded as Most Enthusiastic about R&D by Pharmacists: Nextit survey
December 24, 2007
- R&D NEWS IN BRIEF
December 24, 2007
- Astellas R&D Meeting: Promising PIIb Results Presented on Oral Factor Xa Inhibitor
December 24, 2007
- OPINION／The Power of Positive People Makes My Day
December 24, 2007
- Development Status of New Drugs for IBD Updated: JHSF Seminar
December 24, 2007
- MEDICAL DEVICE NEWS IN BRIEF
December 24, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 24, 2007
- Eisai Goes on the Offensive in Oncology by Acquiring MGI Pharma
December 24, 2007
- Plavix Contributes to Strong Growth in Sales of Antithrombotics: IMS
December 24, 2007
- Record-High Monthly Sales with 500 Fewer MRs: Pfizer Japan
December 24, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…